Alimera expands agreement with Horus Pharma to include marketing Iluvien in the Nordic countries

Alimera and Horus have agreed to expand their relationship beyond France, Belgium, Luxembourg and the Netherlands to increase the commercialization efforts for Iluvien for both diabetic macular edema and non-infectious uveitis affecting the posterior segment of the eye. (Image courtesy of Adobe Stock)

Alimera Sciences Inc. has further expanded its relationship with Horus Pharma (Horus), one of the company’s current distributors of Iluvien in Europe.

According to a news release from the companies, Alimera and Horus have agreed to expand their relationship beyond France, Belgium, Luxembourg and the Netherlands to increase the commercialization efforts for Iluvien for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in the Nordic countries of Denmark, Finland, Norway and Sweden.

“We continue to see great results from Horus selling ILUVIEN and believe they will leverage their marketing and medical expertise to bring ILUVIEN to more patients in these markets,” Rick Eiswirth, president and CEO of Alimera. “Their belief in Iluvien and its ability to treat inflammation consistently and continuously, beginning early in the disease, coupled with their developing commercial infrastructure in these markets, makes Horus the logical partner for the Nordics.”

Claude Claret, CEO of Horus, noted that the company was pleased to develop and expand its collaboration with Alimera.

“We are thrilled with the success of Iluvien in France and Benelux,” added Claude Claret, CEO of Horus. “Iluvien has become an asset for us, helping to drive our expansion throughout Europe. As we launch into the Nordics, we see great potential in this market, which is eagerly awaiting long-acting therapies that can alleviate the burden on healthcare systems.”